Early clinical trials using anti-IGF1R monoclonal antibodies showed promising results in refractory Ewing's sarcomas and rhabdomyosarcomas (Ryan and Goss, 2008). The gene discussed is IGF1R; the disease is rhabdomyosarcoma.